Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2015

01-07-2015 | Editorial

Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

Authors: Sandip Basu, Mitali Dandekar, Amit Joshi, Anil D’Cruz

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2015

Login to get access

Excerpt

One of the most challenging clinical situations in patients with differentiated thyroid cancer (DTC) is an elevated serum thyroglobulin (Tg) level with negative radioiodine scintigraphy (commonly termed “TENIS”). The diagnostic and therapeutic approaches adopted by attending physicians in day-to-day routine vary quite widely. The main reason for this variation is the rarity of the condition (2 – 13 % from various series reported in literature), and its management, especially therapeutic strategies, continues to be imperfect in the absence of a clear-cut understanding and lack of evidence of its aetiology, as observed by various authorities [1]. In this editorial, we discuss the different therapeutic strategies that have been explored and the associated pitfalls in interpretation of clinical findings, and propose a logical step-wise algorithmic approach to care to follow in routine clinics in this particular group of patients. Our views are supported by an overview of the evidence in the literature (with respect to both efficacy and adverse effects) and by practical experience. In addition, we critically review and analyse the steps needed in the immediate future to enhance and rationalize patient care. We believe that such endeavours to identify and prioritize the challenges will further the roadmap to the development of a systematic and scientific approach to the management of patients with TENIS. …
Literature
1.
go back to reference Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41(2):113–20.PubMedCrossRef Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41(2):113–20.PubMedCrossRef
2.
go back to reference Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005;46(7):1164–70.PubMed Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005;46(7):1164–70.PubMed
3.
go back to reference Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079–86.PubMed Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079–86.PubMed
4.
go back to reference Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37(10):953–9.PubMedCrossRef Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37(10):953–9.PubMedCrossRef
5.
go back to reference Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–6.PubMed Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–6.PubMed
6.
go back to reference Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by enhancing expression of the sodium/iodide symporter, thyroperoxidase and thyroglobulin. Endocrinologist. 2004;145:2865–75.CrossRef Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by enhancing expression of the sodium/iodide symporter, thyroperoxidase and thyroglobulin. Endocrinologist. 2004;145:2865–75.CrossRef
7.
go back to reference Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid. 2005;15:594–9.PubMedCrossRef Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid. 2005;15:594–9.PubMedCrossRef
8.
go back to reference Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.PubMedCrossRef Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.PubMedCrossRef
9.
go back to reference Liu D, Xing J, Trink B, Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127(12):2965–73.PubMedCentralPubMedCrossRef Liu D, Xing J, Trink B, Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127(12):2965–73.PubMedCentralPubMedCrossRef
10.
go back to reference Sebai H, Hovsepian S, Ristorcelli E, Aouani E, Lombardo D, Fayet G. Resveratrol increases iodine trapping in the rat thyroid cell line FRTL-5. Thyroid. 2010;20:195–203.PubMedCrossRef Sebai H, Hovsepian S, Ristorcelli E, Aouani E, Lombardo D, Fayet G. Resveratrol increases iodine trapping in the rat thyroid cell line FRTL-5. Thyroid. 2010;20:195–203.PubMedCrossRef
13.
go back to reference Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588–95.PubMedCrossRef Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588–95.PubMedCrossRef
14.
go back to reference Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCentralPubMedCrossRef Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCentralPubMedCrossRef
15.
go back to reference Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–13.PubMedCrossRef Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–13.PubMedCrossRef
16.
go back to reference Sherman SI, Wirth LJ, Droz J-P. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.PubMedCrossRef Sherman SI, Wirth LJ, Droz J-P. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.PubMedCrossRef
17.
go back to reference Pennell NA, Daniels GH, Haddad RI. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;3:317–23.CrossRef Pennell NA, Daniels GH, Haddad RI. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;3:317–23.CrossRef
18.
go back to reference Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008;19:547–52.PubMedCrossRef Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008;19:547–52.PubMedCrossRef
19.
go back to reference Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.PubMedCentralPubMedCrossRef Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.PubMedCentralPubMedCrossRef
20.
go back to reference Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2201–4.PubMedCrossRef Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2201–4.PubMedCrossRef
21.
go back to reference Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. DECISION investigators. Lancet. 2014;384(9940):319–28.PubMedCentralPubMedCrossRef Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. DECISION investigators. Lancet. 2014;384(9940):319–28.PubMedCentralPubMedCrossRef
22.
go back to reference Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621.PubMedCrossRef Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621.PubMedCrossRef
23.
go back to reference Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76:480–3.PubMed Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76:480–3.PubMed
24.
go back to reference Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160–5.PubMedCrossRef Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160–5.PubMedCrossRef
25.
go back to reference Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine unresponsive and rapidly progressive thyroid carcinomas. Thyroid. 2007;17:663–70.PubMedCrossRef Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine unresponsive and rapidly progressive thyroid carcinomas. Thyroid. 2007;17:663–70.PubMedCrossRef
26.
go back to reference Ain KB, Lee C, Holbrook KM, Dziba JM, Williams KD. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol. 2008;26(15S):6027. Abstract. Ain KB, Lee C, Holbrook KM, Dziba JM, Williams KD. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol. 2008;26(15S):6027. Abstract.
27.
go back to reference Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. Hematol Oncol. 2009;2:36–8.CrossRef Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. Hematol Oncol. 2009;2:36–8.CrossRef
28.
go back to reference Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol. 2010;22:464–8.CrossRef Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol. 2010;22:464–8.CrossRef
29.
go back to reference Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab. 2006;17:19–25.PubMedCrossRef Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab. 2006;17:19–25.PubMedCrossRef
30.
go back to reference Jois B, Asopa R, Basu S. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Clin Nucl Med. 2014;39(6):505–10.PubMedCrossRef Jois B, Asopa R, Basu S. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Clin Nucl Med. 2014;39(6):505–10.PubMedCrossRef
31.
go back to reference Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;1154:2052–62.CrossRef Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;1154:2052–62.CrossRef
Metadata
Title
Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap
Authors
Sandip Basu
Mitali Dandekar
Amit Joshi
Anil D’Cruz
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3058-x

Other articles of this Issue 8/2015

European Journal of Nuclear Medicine and Molecular Imaging 8/2015 Go to the issue